Details

Autor(en) / Beteiligte

• Sawmiller, Darrell
• Li, Song
• Shahaduzzaman, Md
• Smith, Adam J
• Obregon, Demian
• Giunta, Brian
• Borlongan, Cesar V
• Sanberg, Paul R
• Tan, Jun

Titel

Luteolin reduces Alzheimer's disease pathologies induced by traumatic brain injury

Ist Teil von

• International journal of molecular sciences, 2014-01, Vol.15 (1), p.895-904

Ort / Verlag

Switzerland: Molecular Diversity Preservation International (MDPI)

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Traumatic brain injury (TBI) occurs in response to an acute insult to the head and is recognized as a major risk factor for Alzheimer's disease (AD). Indeed, recent studies have suggested a pathological overlap between TBI and AD, with both conditions exhibiting amyloid-beta (Aβ) deposits, tauopathy, and neuroinflammation. Additional studies involving animal models of AD indicate that some AD-related genotypic determinants may be critical factors enhancing temporal and phenotypic symptoms of TBI. Thus in the present study, we examined sub-acute effects of moderate TBI delivered by a gas-driven shock tube device in Aβ depositing Tg2576 mice. Three days later, significant increases in b-amyloid deposition, glycogen synthase-3 (GSK-3) activation, phospho-tau, and pro-inflammatory cytokines were observed. Importantly, peripheral treatment with the naturally occurring flavonoid, luteolin, significantly abolished these accelerated pathologies. This study lays the groundwork for a safe and natural compound that could prevent or treat TBI with minimal or no deleterious side effects in combat personnel and others at risk or who have experienced TBI.